Celldex Therapeutics, Inc. announced that the first patient has been screened in a randomized Phase 2 study of the Company’s novel, first-in- class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. Source: General Cancer News Articles Provided by Cancer Compass
Study finds cancer mortality has declined since initiation of ‘war on cancer’ ( American Cancer Society ) A new American Cancer Society study finds progress in reducing cancer death rates is evident whether measured against baseline rates in 1970 or in 1990. The study appears in the open access journal PLoS ONE, and finds a downturn [...]
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Source: General Cancer News Articles Provided [...]
ArQule, Inc. announced the initiation of a Phase 2, single agent trial with ARQ 197 in germ cell tumors (GCT), including testicular and non- central nervous system (non-CNS) tumors, and a Phase 1/2 clinical trial designed to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab [...]